Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

TL1A antibodies: a new inflammatory disease market

As late-stage trials accumulate and candidates get closer to market, find out about TL1A, a new class in inflammatory diseases. The post TL1A antibodies: a new inflammatory disease market appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly…

We haven't written up this one. Labiotech has the full story — the link below goes straight to it.

Read the original at labiotech.eu →

More in Finance & Markets

Is Apple Losing Its Memory?

In the first earnings report under new CEO John Ternus, Apple faces supply chain challenges and questions about what to do with all that extra cash.

More from Monday 16 November →